Search results
Results From The WOW.Com Content Network
Arena Pharmaceuticals, Inc. is an American biopharmaceutical company founded in 1997 and headquartered in San Diego, California. [3] The company has small molecule drugs in development for possible clinical utility in multiple therapeutic areas.
Arena Pharmaceuticals (NAS: ARNA) is revving up for the launch of its obesity drug, Belviq. The drug was the first obesity drug approved earlier this year but got held back by DEA scheduling while ...
Arena (ARNA) inks a deal to out-license global rights to its phase III candidate, ralinepag, to United Therapeutics. Shares of the company rally 22% following this news.
Arena Pharmaceuticals (NAS: ARNA) is a clinical-stage biopharmaceutical company focused on developing oral drugs that treat cardiovascular, central nervous system, inflammatory, and metabolic ...
Pfizer (PFE) signs an agreement to acquire Arena Pharmaceuticals for $6.7 billion in cash. Stock rises.
Arena Pharmaceuticals' shareholders -- and those who short the stock, for that matter -- are anxiously awaiting the launch of the company's obesity drug Belviq. The Food and Drug Administration ...
Let's look at Arena Pharmaceuticals (NAS: ARNA) today and Examine its pros and cons, and decide whether it's possible upside outweighs its risks. Buy, Sell, or Hold: Arena Pharmaceuticals
Giant pharmaceutical company Pfizer agreed earlier today to acquire Arena Pharmaceuticals in a deal worth roughly $6.7 billion.